Anti-Fungal Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Othe
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAnti-Fungal Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Othe
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 10.04 Billion |
| CAGR (2023-2028) | 3.18% |
| Fastest Growing Segment | Azoles |
| Largest Market | North America |
Market Overview
Key Market Drivers
Rising Prevalence of Fungal Infections
Increasing Hospitalizations
Increasing Investment for Healthcare Infrastructure
Increasing Number of Antifungal Drugs as Over the counter (OTC)
Key Market Challenges
Adverse Health Effects
Increasing Resistance to Antifungal Drugs
Key Market Trends
Increase In the Number of Research and Development Activities
Technological Progress in Diagnostic Tests and Devices
Segmental Insights
Drug Class Insights
In 2022, the Azoles medicine class segment, which includes popular therapeutics such as Noxafil, Diflucan, Vfend, and Cresemba, emerged as the leading market segment for antifungal drugs. This dominance can be attributed to the broad spectrum of activity exhibited by Azoles. By inhibiting fungal enzymes, these substances facilitate fungistatic actions. Azoles are prescribed for the treatment of ocular fungal infections, systemic candidiasis, blastomycosis, and candidemia. Triazoles and imidazoles, two types of azoles, are also utilized for managing systemic fungal infections due to their extensive range of activity and favorable safety profile. Triazoles possess superior absorption and distribution characteristics, fewer side effects, and minimal risk of drug interactions.
The market for antifungal medications is expected to witness slow growth, primarily due to the escalating drug resistance among Candida and Aspergillus species, particularly against azoles. Conversely, synthetic fungicidal compounds called allylamines are projected to exhibit a steady compound annual growth rate (CAGR) throughout the forecast period. These medications are recommended for the treatment of ringworm, athlete's foot, jock itch, and nail infections. Following fluconazole, Lamisil is the topical antifungal drug most frequently recommended by dermatologists for systemic antifungal therapy. Consequently, the increasing prevalence of dermatological conditions is anticipated to further augment the growth of this segment.
Indication Insights
The most prevalent systemic fungal infection, candidiasis, is projected to have the highest compound annual growth rate (CAGR) during the forecast period. It is caused by the Candida genus and its treatment has evolved over time. Appropriate use of echinocandins and broad-spectrum azoles is recommended for the treatment of mucosal candidiasis, candidemia, and invasive candidiasis, among other changes. The increasing number of individuals susceptible to fungal infections is a significant driver for the market. Furthermore, the growing awareness among patients and healthcare professionals is expected to contribute to the demand for antifungal medications.
The dermatophytosis category is expected to hold a significant market share throughout the forecast period due to the rising prevalence of skin infections in children. Unhealthy lifestyles have contributed to a significant increase in the prevalence of this infection over the past decade. Immunocompromised patients are particularly concerned due to their susceptibility to severe lesions and atypical symptoms caused by fungi.
Other indications include endocarditis, rhino-cerebral mucormycosis, and invasive pulmonary aspergillosis. One of the main challenges faced by physicians is the limited treatment options found at for invasive fungal infections compared to bacterial infections. Only a few therapeutic molecule classes have been developed in the past 30 years. Developing effective therapeutic drugs for managing systemic fungal infections in immunocompromised patients is a key area of interest for industry players. The exploration of innovative therapies through public-private partnerships is expected to offer significant growth potential for the industry.
Regional Insights
Recent Developments
- June 2022Apex Labsunveiled the advanced Supra Bioavailable Itraconazole 65 and 130 mg capsules, apotent therapeutic option for effectively managing fungal infections. SupraBioavailable Itraconazole capsules deliver a higher percentage (90 percent) ofactive medicine to the biological system with a reduced dosage. This advancedformulation also ensures minimal inter-individual variability, potentiallyleading to improved efficacy in fungal infection management, as stated by thecompany.
- April 2022TheUnited States Food and Drug Administration (US FDA) granted approval for VIVJOA(oteseconazole capsules), an azole antifungal indicated for the reduction ofrecurrent vulvovaginal candidiasis (RVVC) in females. VIVJOA represents thefirst and only FDA-approved medication for this condition and serves as MycoviaPharmaceuticals, Inc.'s inaugural FDA-approved product.
- June 2021MankindPharma introduced Posaconazole Gastro, a novel medication utilized in thetreatment of black fungus, known for its resistance. It has been identified asa preferred medicine for safer and more effective disease management. The DrugController General of India (DCGI) has granted approval for this medication.
Key Market Players
- Abbott Laboratories Inc.
- Astellas Pharma Inc.
- Bayer AG
- GSK plc
- Glenmark Pharmaceuticals Limited
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Mycovia Pharmaceuticals, Inc.
- Apex Laboratories Pvt. Ltd.
| By Drug Class | By Indication | By Infection Type | By Route of Administration | By End User | By Distribution Channel | By Region | |
|
|
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy